Long-term inhaled dry powder mannitol in cystic fibrosis: An international randomized study

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 6, 2012, Pages 645-652

  Aitken, Moira L ^a   Bellon, Gabriel ^b   De Boeck, Kris ^c   Flume, Patrick A ^d   Fox, Howard G ^e   Geller, David E ^f   Haarman, Eric G ^g,h   Hebestreit, Helge U ⁱ   Lapey, Allen ^j   Schou, I Manjula ^e   Zuckerman, Jonathan B ^k   Charlton, Brett ^e  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Hopital Femme Mere Enfants Service Pediatrie Unite Pneumologie/ Allergologie   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Pharmaxis Ltd   (Australia)

^f NEMOURS CHILDREN S HOSPITAL   (United States)

^g EMMA CHILDREN S HOSPITAL   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j GENERAL HOSPITAL   (United States)

^k MAINE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG FEVER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LABORATORY TEST; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORBIDITY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SORE THROAT; SPIROMETRY; SPUTUM ANALYSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DIURETICS, OSMOTIC; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MANNITOL; MIDDLE AGED; MUCOCILIARY CLEARANCE; POWDERS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858234304     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201109-1666OC     Document Type: Article

References (25)

1. Puchelle E, Bajolet O, Abely M. Airway mucus in cystic fibrosis. Paediatr Respir Rev 2002;3:115-119. (Pubitemid 35331504)
2. Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest 2007;132:1631-1636. (Pubitemid 350156022)
3. Committee for Medicinal Products for Human Use. Guidelines on the clinical development of medicinal products for the treatment of cystic fibrosis. [Internet; accessed 2011 Oct]. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/12/WC500017055. pdf
4. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009;54:595-605.
5. Davies JC, Alton EWFW, Bush A. Cystic fibrosis. BMJ 2007;335:1255-1259.
6. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al.; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969. (Pubitemid 350127838)
7. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997;10:2449-2454. (Pubitemid 28048614)
8. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertson CF, Bye PT, Lesouëf PN, Shadbolt B, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-1396. (Pubitemid 351892995)
9. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010;137:861-868.
10. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe K, Fox H, Jaques A, Charlton B; for the CF301 Study Investigators. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38:1071-1080.
11. Dodge JA, Lewis PA, Stanton M,Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526. (Pubitemid 46372100)
12. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814. (Pubitemid 28027602)
13. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230-1234. (Pubitemid 28223809)
14. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72. (Pubitemid 34114229)
15. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352. (Pubitemid 32144560)
16. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182:627-632.
17. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibros 2011;10:1-8.
18. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-187. (Pubitemid 29036522)
20. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338. (Pubitemid 41079078)
22. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354. (Pubitemid 41507578)
23. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
24. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-1715.
25. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011;473:216-220.